Comparison of Effectiveness of Apremilast versus Methotrexate and Apremilast in Patients with Chronic Plaque Psoriasis
DOI:
https://doi.org/10.37018/PEGI3677Keywords:
Chronic plaque psoriasis, Apremilast, Methotrexate, PASI score, EfficacyAbstract
Background: Chronic plaque psoriasis is a prevalent, immune-mediated skin disorder characterized by erythematous plaques with silvery scales. The condition significantly impacts patients’ quality of life, necessitating effective treatment strategies.
Objective: To compare the efficacy of apremilast versus methotrexate plus apremilast in patients with chronic plaque psoriasis.
Methods: This prospective observational study was conducted at the Outpatient Department of Dermatology Services Hospital, Lahore. After getting approval from Ethical Review Committee, sixty patients of plaque psoriasis were observed in two groups of thirty patients each, depending on which treatment they were taking. Group A patients received apremilast, while Group B received oral methotrexate combined with apremilast. The primary outcome was the achievement of PASI 75 (75% reduction in Psoriasis Area and Severity Index) after three months of treatment. Patients were followed up after 3 months for calculation of PASI.
Results: The study included 34 males (56.7%) and 26 females (43.3%), with a mean age of 42.80 ± 10.68 years. The baseline PASI score significantly reduced from 28.25 ± 5.86 to 7.09 ± 2.18 after three months. The mean percentage reduction in PASI score was 69.89 ± 11.22% in Group A and 76.76 ± 9.80% in Group B. Efficacy was observed in 42.9% of patients in Group A and 57.1% in Group B, which was statistically significant (p value =0.014).
Conclusion: The combination of methotrexate and apremilast was more effective than apremilast alone in treating chronic plaque psoriasis.
Downloads
Published
How to Cite
Issue
Section
License
The Journal of Fatima Jinnah Medical University follows the Attribution Creative Commons-Non commercial (CC BY-NC) license which allows the users to copy and redistribute the material in any medium or format, remix, transform and build upon the material. The users must give credit to the source and indicate, provide a link to the license, and indicate if changes were made. However, the CC By-NC license restricts the use of material for commercial purposes. For further details about the license please check the Creative Commons website. The editorial board of JFJMU strives hard for the authenticity and accuracy of the material published in the journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board.
